Slow Bureaucracy Drives Indian Drug Makers Abroad For Approvals
This article was originally published in PharmAsia News
Indian drug makers complain their government takes too long to approve clinical trials, leading many of them to go to other countries for faster clearance. Piramal Life Sciences said it turned to Canada after waiting seven months for approval to conduct a trial and got Health Canada's approval within 28 days. Swati Piramal, director of the parent Piramal Group, said India's drug-regulation system is archaic and blocks efforts by Indian drug makers to use their home country to a competitive advantage. Part of the problem stems from insufficiently informed bureaucrats at the regulatory agency. (Click here for more - a subscription may be required
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.